Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Acetate→

Potassium Acetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
127-08-2
Molecular formula
C2H3KO2
Molecular weight
98.14 g/mol
Drug class
Potassium saltintravenous electrolyte replacement and alkalinising precursor
Mechanism of action
Dissociates to provide potassium ions, which are essential for resting membrane potential, neuromuscular transmission and cardiac conduction. Acetate is metabolised to bicarbonate and can contribute to alkalinisation.
Indications / reported uses
  • Prevention and treatment of potassium depletion when intravenous replacement is indicated, particularly when chloride administration is undesirable; dose and infusion rate require electrolyte and cardiac monitoring

Sources: US DailyMed — Potassium acetate injection · NLM MeSH — Potassium acetate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Potassium Acetate Environmental Risk Assessment (ERA) (the Potassium Acetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.